Evidence map›Paper›PMID 40495098›Full record

ReviewAAPS PharmSciTech2025

Unveiling the Potential of Nanoclays in Pharmaceuticals.

Rabab Kamel, Giuseppina Nocca, Elena Mazzinelli, Somaia S Abd El-Karim, Valerio Papa, Ilaria Cacciotti, Nermeen A Elkasabgy

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Self-Assembling Short Peptide Carriers for Gene Delivery.International journal of molecular sciences · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rabab KamelPharmaceutical Technology Department, National Research Centre, Cairo, 12622, Egypt. drrababk@hotmail.com.ORCID http://orcid.org/0000-0003-1017-527X
Giuseppina NoccaDipartimento Di Scienze Biotecnologiche Di Base, Cliniche Intensivologiche E Perioperatorie, Sezione Di Biochimica, Università Cattolica del Sacro Cuore (UCSC), Largo Francesco Vito 1, 00168, Rome, Italy.
Elena MazzinelliDipartimento Di Scienze Biotecnologiche Di Base, Cliniche Intensivologiche E Perioperatorie, Sezione Di Biochimica, Università Cattolica del Sacro Cuore (UCSC), Largo Francesco Vito 1, 00168, Rome, Italy.
Somaia S Abd El-KarimDepartment of Therapeutic Chemistry, National Research Centre, Cairo, 12622, Egypt.
Valerio PapaEngineering Department, INSTM RU, University of Rome Niccolò Cusano, Via Don Carlo Gnocchi 3, 00166, Rome, Italy.
Ilaria CacciottiEngineering Department, INSTM RU, University of Rome Niccolò Cusano, Via Don Carlo Gnocchi 3, 00166, Rome, Italy.
Nermeen A ElkasabgyDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clay minerals or nanoclays are layered aluminosilicate nanoparticles with unique physicochemical properties, excellent biocompatibility, high surface area, lamellar structure, diverse ion-exchange capacity, tuneable surface chemistry enabling them to form different intermolecular interactions which offer supreme prospects for optimized pharmaceutical applications. This review article dives into the key characteristics of different types of nanoclays like Halloysite, Kaolinite, Sepiolite, Montmorillonite, Bentonite and Laponite, highlighting their possible exploitation within the pharmaceutical landscape. Also, the review describes the recent advances in nanoclay-based drug delivery systems and discusses the role of nanoclays as drug carriers and their use in tissue engineering and gene therapy. Nanoclays, are used to modulate drug release and stabilize the loaded active molecules as well as to enhance drug loading. Interdisciplinary research, advanced characterization techniques, and careful formulation designs are required to augment the use of nanoclays in various pharmaceutical applications. Despite the faced challenges, research on nanoclay-based drug delivery systems is growing. With targeted research and development, nanoclays are poised to redefine the biomedical domain, offering tailored and efficient therapies for a multitude of diseases.

Indexed as

Aluminum SilicatesClayDrug CarriersNanoparticlesChemistry, PharmaceuticalDrug Delivery SystemsDrug LiberationGenetic TherapyHumansPharmaceutical PreparationsTissue EngineeringAluminum SilicatesClayDrug CarriersPharmaceutical PreparationsAluminosilicateControlled releaseDrug delivery and therapeuticsNanoclaysNanolayers

Identifiers

PMID40495098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.